Tag: KRASG12C

Mirati Therapeutics Inc’s (NASDAQ: MRTX) SAPPHIRE study did not meet its primary endpoint of overall survival at the final analysis. SAPPHIRE is a Phase 3 study evaluating sitravatinib plus Bristol-Myers Squibb Co’s (NYSE: BMY) Opdivo (nivolumab) versus docetaxel in patients with second or third-line advanced non-squamous non-small cell lung cancer who progressed on prior…

Genomic studies of cancer patients have revealed thousands of mutations linked to tumor development, but researchers are unsure how the vast majority of these mutations contribute to cancer because there’s no easy way to study them in animal models. Massachusetts Institute of Technology researchers have now developed a way to…

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. BEIJING–(BUSINESS WIRE)– Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust oncology pipelines were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting. Oral Presentation: ICP-490 is…

ROCKVILLE, Md. and SUZHOU, China, March 21, 2023  /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, today announced that clinical data from multiple trials in relation to…

Clinical Validation of Plasma Cell-Free DNA (cfDNA) Sequencing in a Phase 2 Cohort of the KRYSTAL-1 Study of Adagrasib in Patients with KRASG12C-Mutated NSCLC | Mirati Therapeutics, Inc. Fullscreen Mode …

Background Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRASG12C. We compared the efficacy and safety of sotorasib with a standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRASG12C mutation who had been previously treated with other anticancer drugs. Methods We conducted a randomised, open-label…

– Fourth Quarter 2022 Total Revenue of $36.3 Million and Full Year 2022 Revenue of $134.0 Million; QINLOCK® Net Product Revenue Increased 44% to $125.5 Million in 2022 Compared to 2021 – – Expects to Complete Enrollment in the MOTION Pivotal Phase 3 Study of Vimseltinib in the First Quarter…

DUBLIN–(BUSINESS WIRE)–The “Global KRAS Inhibitors Market & Clinical Trials Forecast 2028” report has been added to ResearchAndMarkets.com‘s offering. The advancement in clinical research has led to the identification of several oncogenes that are generally mutated in cancers. Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most frequently mutated…

Introduction Most cases of pancreatic adenocarcinoma (PDAC) are diagnosed in the metastatic or locally advanced stage. It is the fourth leading cause of cancer death in the United States,1,2 with a 5-year overall survival (OS) around 10% in this country2 despite years of research and therapeutic development. For those patients…

Next-Generation Sequencing Utilizing Tumor Tissue and/or Blood The identification of actionable genomic alterations in tumors such as mCRC was once performed by Sanger DNA sequencing of tumor DNA that was extracted from fixed paraffin-embedded tumor tissue, but this has now been replaced by next-generation sequencing (NGS), which allows for larger-scale…